Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of ticilimumab in refractory metastatic colorectal adenocarcinoma
2006-001270-24Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2006
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in colon adenocarcinoma and rectal adenocarcinoma, sponsored by Pfizer. Primary endpoint: Best overall response rate per RECIST. Started May 2006; status: terminated.
02
Drugs
tremelimumab
03
Conditions
colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2006-001270-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001270-24.